Q32 Bio (QTTB) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025 summary

Key clinical insights and data

• Lead asset bempikibart targets IL-7 and TSLP, showing promise in TH2 and TH1-mediated diseases, especially alopecia areata, with durable hair regrowth out to 36 weeks and beyond.

• Patients demonstrated maintenance and even deepening of hair regrowth after treatment cessation, suggesting a remissive or disease-modifying effect not seen with JAK inhibitors.

• Biomarker data confirm robust pharmacodynamic effects, including significant reductions in TH2 markers and T cell subsets, with high receptor occupancy and minimal immunogenicity.

• Clinical images and follow-up data show continued hair regrowth up to 55 weeks post-treatment, with high patient and investigator enthusiasm.

• KOLs and trial sites express strong interest, with high anticipated demand for enrollment in upcoming studies.

Strategic focus and pipeline updates

• Development resources are being concentrated on bempikibart in alopecia areata, with the complement platform paused and strategic options being explored for those assets.

• Part B of the clinical program will introduce a loading regimen, longer treatment (36 weeks), and extended follow-up (52 weeks) to further assess remissive potential.

• Open label extension and Part B trials are set to begin in the first half of the year, with data readouts expected in the first half of 2026.

• The company holds $89.1 million in cash, providing runway into the second half of 2026 and supporting key clinical milestones.

• Strategic partnerships are being sought for the complement platform, with a shift away from crowded renal indications.

Market opportunity and future directions

• Alopecia areata affects 700,000 US patients, with 300,000 severe cases and only 30,000 currently treated with JAK inhibitors.

• The market is projected to grow from $1 billion in 2026 to $2.6 billion, with no biologic competitors currently available.

• Bempikibart’s safety and efficacy profile positions it as a potential first-in-class biologic for AA, with transformative potential and high patient preference for safer injectable options.

• Future expansion is considered for other autoimmune diseases, including RA, ulcerative colitis, and TH2/TH1-driven conditions, based on preclinical and biomarker data.

• Maintenance dosing strategies and potential tissue biomarker studies are under consideration for future trials.